Logo
  • Careers
  • Contact Us
  • Donate
  • Subscribe
Search
  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
      • HIV Vaccine Translational Research Laboratory
      • Human Immunology Laboratory
      • IAVI Neutralizing Antibody Center
      • Vaccine Design and Development Laboratory
    • Translation & Product Development
    • Clinical & Epidemiology Research
      • ADVANCE
      • Clinical Research Centers
      • Clinical Research Standards
      • HIV Epidemiology
    • Global Community Engagement
      • Africa Program
      • CASPR
      • End-User Research
      • World Bank/Japan-supported
        Partnerships | 日本政府・世銀が支援するパートナーシップ
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
  • Careers
  • Contact Us
  • Donate
  • Subscribe

Search

  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
    • Translation & Product Development
    • Clinical & Epidemiology Research
    • Global Community Engagement
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
COVID-19
  • Latest NewsLatest News
  • Scientific Publications Scientific Publications
  • Press Releases
  • Features
  • IAVI Report
  • IAVI in the News
  • Fact Sheets & Publications
  • VOICES Newsletter
  • Media Contacts
  • Subscribe

Scientific Publications

Filter By:

 

 
Filters

Schultz AM, Bradac JAThe HIV vaccine pipeline, from preclinical to phase III. AIDS 2001;15 Suppl 5:S147-58

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

McMichael A, Hanke TThe quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2002;2(4):283-91

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

The rationale for developing anti-HIV vaccines that stimulate cytotoxic T-lymphocyte responses is given. We argue that such vaccines will work, provided that attention is paid to the development of memory T-cell responses that are strong and preferably activated. Furthermore, the vaccine should match the prevailing virus clade as closely as possible. Vaccines will have to stimulate a wide range of responses, but it is not clear how this can be achieved.

Wee EG, Patel S, McMichael AJ, Hanke TA DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 2002;83(Pt 1):75-80

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary HIV isolates or elicitation of broad T cell-mediated immune responses. Here, we showed in rhesus macaques that the very same vaccines that had entered clinical trials in Oxford and Nairobi, plasmid pTHr.HIVA DNA and recombinant modified vaccinia virus Ankara MVA.HIVA in a prime-boost protocol (Hanke & McMichael, Nature Medicine 6, 951-955, 2000), induced cellular immune responses specific for multiple HIV-derived epitopes. This was demonstrated by using the intracellular cytokine staining and ELISPOT assays detecting interferon-gamma and pools of peptides employed in the clinical studies. These results have both boosted our expectations for the performance of these vaccines in humans and increased our confidence about the choice of these assays as the primary readouts in the on-going human trials.

Wheeler C, Berkley SInitial lessons from public-private partnerships in drug and vaccine development. Bull. World Health Organ. 2001;79(8):728-34

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

In recent years, venture capital approaches have delivered impressive results in identifying and funding promising health discoveries and bringing them to market. This success has inspired public sector experiments with 'social venture capital' approaches to address the dearth of affordable treatment and prevention for diseases of the developing world. Employing the same focus on well-defined and measurable objectives, and the same type of connections to pool and deploy resources as their for-profit counterparts, social venture capitalists seek to use the tools and incentives of capitalism to solve one of its biggest failures: the lack of drugs and vaccines for diseases endemic to low-income populations. As part of a larger trend of partnerships emerging in health product donation and distribution, public-private partnerships for pharmaceutical development have led research and development (R&D) efforts to generate more accessible and efficacious products for diseases such as malaria, tuberculosis, and AIDS. In this article, three R&D-focused partnerships are explored: the International AIDS Vaccine Initiative; the Medicines for Malaria Venture; and the newly formed Global Alliance for TB Drug Development. The article highlights key elements essential to the success of these ventures.

Johnston MIHIV/AIDS Vaccine Development: Challenges, Progress and Future Directions. Rev. Med. Virol. 1996;6(3):123-140

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Berkley S

HIV vaccine development for the world: an idea whose time has come? AIDS Res. Hum. Retroviruses 1998;14 Suppl 3:S191-6

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Page 87 of 87

StartPrev787980818283...858687
Next
End

About

About

Board of Directors

Senior Leadership

Financial Statements

Global Funding & Support

Our Work

Our Work

Discovery

Translation & Product Development

Clinical & Epidemiology Research

Global Community Engagement

IAVI DataSpace

Our Science

Our Science

Pipeline

HIV Vaccines

bnAbs for HIV Prevention

Tuberculosis Vaccines

Emerging Infectious Diseases Vaccines and Therapeutics

Snakebite

News & Resources

Latest NewsLatest News

Scientific Publications Scientific Publications

Press Releases

Features

IAVI Report

IAVI in the News

Fact Sheets & Publications

VOICES Newsletter

Media Contacts

Subscribe

icon charity navigator icon guide star icon iavi

Accessibility

Compliance

Contact IAVI

Privacy Policy

Site Map

Supplier Diversity

Terms of Use

©2021 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the International AIDS Vaccine Initiative, Inc.